209 related articles for article (PubMed ID: 21764390)
1. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
Ibrahim T; Sacanna E; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Ricci R; Serra L; Kang Y; Amadori D
Clin Breast Cancer; 2011 Dec; 11(6):369-75. PubMed ID: 21764390
[TBL] [Abstract][Full Text] [Related]
2. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study.
Sacanna E; Ibrahim T; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Bravaccini S; Ricci R; Serra L; Amadori D
Oncology; 2011; 80(3-4):225-31. PubMed ID: 21734413
[TBL] [Abstract][Full Text] [Related]
3. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
4. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
6. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
7. Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases.
Todenhöfer T; Hennenlotter J; Schmiedel BJ; Hohneder A; Grimm S; Kühs U; Salih HR; Bühring HJ; Fehm T; Gakis G; Blumenstock G; Aufderklamm S; Schilling D; Stenzl A; Schwentner C
Prostate; 2013 Jan; 73(2):162-8. PubMed ID: 22715006
[TBL] [Abstract][Full Text] [Related]
8. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
9. Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis.
Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
J Clin Pathol; 2012 Jan; 65(1):36-40. PubMed ID: 22049226
[TBL] [Abstract][Full Text] [Related]
10. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
11. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
Sasaki A; Ishikawa K; Haraguchi N; Inoue H; Ishio T; Shibata K; Ohta M; Kitano S; Mori M
Ann Surg Oncol; 2007 Mar; 14(3):1191-9. PubMed ID: 17195907
[TBL] [Abstract][Full Text] [Related]
12. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 expression in early breast cancer and risk of distant recurrence.
Andre F; Xia W; Conforti R; Wei Y; Boulet T; Tomasic G; Spielmann M; Zoubir M; Berrada N; Arriagada R; Hortobagyi GN; Hung MC; Pusztai L; Delaloge S; Michiels S; Cristofanilli M
Oncologist; 2009 Dec; 14(12):1182-8. PubMed ID: 19939894
[TBL] [Abstract][Full Text] [Related]
14. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
[TBL] [Abstract][Full Text] [Related]
15. Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer.
Hiller DJ; Meschonat C; Kim R; Li BD; Chu QD
Surgery; 2011 Sep; 150(3):459-65. PubMed ID: 21878231
[TBL] [Abstract][Full Text] [Related]
16. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
17. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
18. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
19. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.
Santini D; Perrone G; Roato I; Godio L; Pantano F; Grasso D; Russo A; Vincenzi B; Fratto ME; Sabbatini R; Della Pepa C; Porta C; Del Conte A; Schiavon G; Berruti A; Tomasino RM; Papotti M; Papapietro N; Onetti Muda A; Denaro V; Tonini G
J Cell Physiol; 2011 Mar; 226(3):780-4. PubMed ID: 20857484
[TBL] [Abstract][Full Text] [Related]
20. Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases.
Milone F; Pivonello C; Cariati F; Sarnataro M; Ramundo V; Marotta V; Jann H; Pape UF; Wiedenmann B; Colao A; Pavel M; Faggiano A
Biomarkers; 2013 Mar; 18(2):121-5. PubMed ID: 23336103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
